national security corporation, page-8

This is certainly being watched in the USA.

Mentor Capital Sees a Shift to Public Acceptance of Dendreon-like Cancer Immunotherapy Treatments and Companies in Fox News Coverage of Provenge



SAN DIEGO, Apr 26, 2010 (BUSINESS WIRE) -- Mentor Capital, Inc. (Pink Sheets:MNTR) notes the featuring of Dendreon's /quotes/comstock/15*!dndn/quotes/nls/dndn (DNDN 41.19, +1.09, +2.72%) Provenge prostate cancer vaccine on Fox News is a certain sign that cancer immunotherapy has come to a point of popular acceptance in the public mind. One year ago only biotech investment reviews and medical journal reports followed pioneering Cancer Immunotherapy Index member Dendreon as it climbed 1,000% in forty-five days.

Dendreon continues to lead the Index in the FDA approval race. Mentor Capital anticipates a positive FDA announcement for Provenge to be reported at month-end. This will be a significant milestone not only for Dendreon, but also for the several Dendreon-like companies in the Cancer Immunotherapy Index that use the same approach. Different cancers are fought by attacking their different cancer proteins, but the general mobilization of the human immune system is similar.

In addition to Dendreon's possible pending treatment for prostate cancer, other Cancer Immunotherapy Index Companies are also pursuing treatments targeting cancer stem cells or brain, breast, melanoma and other cancer immunotherapies. Quite possibly, two or three markets of equal or greater size to Dendreon's will evolve from the Cancer Immunotherapy Index companies, simply because there are two or three times the occurrence of cancer in the other cancer types that those companies are working on.

Perhaps because the relative opportunity favors the smaller Index companies, Dendreon's extraordinary annual rate of stock price appreciation, including today's early price jump, is only 100% growth, compared to the overall Index annualized rate of growth of 125%, since Index formation July 2009.